Novozymes and Sanofi-Aventis Collaborate for Potential Antibiotic
Novozymes (Bagsvaerd, Denmark) has entered into a global licensing and collaboration agreement with Sanofi-Aventis (Paris, France) for the development and marketing of a new potential antibiotic.
Novozymes (Bagsvaerd, Denmark) has entered into a global licensing and collaboration agreement with Sanofi-Aventis (Paris, France) for the development and marketing of a new potential antibiotic.
The drug candidate, developed by Novozymes, is an antimicrobial peptide named Plectasin NZ2114, a variant of plectasin, for the treatment of severe infections, such as pneumonia and septicemia, caused by resistant and sensitive gram-positive bacteria like Staphylococcus and Streptococcus.
Under the terms of the agreement, Sanofi-Aventis has been granted an exclusive worldwide license for the development, registration, and commercialization of the drug. The two parties will jointly work to develop and implement commercial-scale manufacturing of the Plectasin NZ2114 drug substance.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
